Oppenheimer lowered the firm’s price target on Alumis (ALMS) to $26 from $32 and keeps an Outperform rating on the shares. The firm says the ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

Alumis and Acelyrin have announced a definitive merger agreement, which will result in an all-stock transaction, creating a ...

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

A live webcast will be available on the Alumis website in the "Investors" section under the “Events” page. About Alumis Alumis is a clinical-stage biopharmaceutical company developing oral therapies ...

SOUTH SAN FRANCISCO, Calif. - Alumis Inc. (NASDAQ: ALMS), currently valued at $388 million and trading near its 52-week low of $6.29, and ACELYRIN, INC. (NASDAQ: SLRN) have entered into a definitive ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

H.C. Wainwright analyst Mitchell S. Kapoor revised the price target on Alumis Inc (NASDAQ:ALMS) to $19.00, down from the previous target of $26.00, while retaining a Buy rating for the company's ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Alumis Inc. (NASDAQ: ALMS) and ACELYRIN ...

Alumis (ALUM) stock dropped while Acelyrin (SLRN) stock gained in the premarket as the biopharma companies announced an all-stock merger deal. Read more here.

Alumis Inc. SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision ...